Navigation Links
Mylan Selected as a Leading ARV Supplier to India's National AIDS Control Organization
Date:9/4/2012

HYDERABAD, India and PITTSBURGH, Sept. 4, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Laboratories Limited has been selected as a leading supplier of antiretroviral (ARV) drugs to India's National AIDS Control Organization (NACO). NACO is a division of India's Ministry of Health and Family Welfare and is responsible for overseeing HIV/AIDS control programs in India. NACO's objective is to halt and reverse the HIV/AIDS epidemic in India over the next five years through integrated programs for prevention, care and support and treatment. NACO manages 35 HIV Prevention and Control Societies, which implement NACO's programs at the State level and manage more than 350 ARV treatment centers.

Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's 7 billion people access to high quality medicines, and helping to ensure access to high quality, affordable ARVs is a core part of this mission. Only through access to these vital medicines can we stem the tide of HIV/AIDS in India and around the world. We are honored that Mylan has been selected as a significant supplier to NACO and look forward to helping this critical organization achieve its mission."

Approximately one-third of HIV/AIDS patients in developing countries depend on a Mylan ARV product, and Mylan has recently entered the Indian commercial market, starting with a portfolio of ARV drugs. Mylan's wide range of ARV products includes active pharmaceutical ingredients and 43 first- and second-line finished doses, nine of which are pediatric products.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
2. Mylan Launches Lithium Carbonate Extended-Release Tablets USP
3. Mylan Launches Commercial Operations in India, Starting with a Broad, Innovative Portfolio of ARV Products to Treat HIV/AIDS
4. Mylan Applauds Study Highlighting $1 Trillion in Savings for U.S. Health Care System Due to Generic Drugs Over Past Decade
5. Mylan Schedules Second Quarter 2012 Financial Results Conference Call and Live Webcast
6. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
7. Mylan Launches Thiamine Hydrochloride Injection
8. Mylan Launches Generic Version of Lipitor®
9. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
10. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
11. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... JERUSALEM , May 9, 2017  Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Canadian Intellectual Property Office has ... for Oral Administration of Exenatide". The patent covers ... analog. GLP-1 is an incretin hormone ...
(Date:5/8/2017)... -- MACRA replaces the outdated sustainable growth rate ... Black Book Research crowdsource-surveyed 8,845 physician practices from February ... for MIPS Compliance Technology is Booming ... or more clinicians seek to buy Merit-Based Incentive Payment ... of the changes, the hunt is on for the ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... ... ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with machine ... IT system, from the datacenter to the cloud to the edge. Through the ...
(Date:5/24/2017)... Massapequa Park, NY (PRWEB) , ... May 24, ... ... today announced the practice is offering holistic pediatric dentistry options for its patients ... the context of the patient’s entire physical well being, and is one of ...
(Date:5/24/2017)... Chicago, IL (PRWEB) , ... May 24, 2017 ... ... of the most prominent for-profit and nonprofit hospitals and health systems in the ... have turned around their institutions, led professional organizations and been instrumental in developing ...
(Date:5/24/2017)... West Orange, NJ (PRWEB) , ... May 24, 2017 , ... ... ingredients for avoiding back injury when either lifting weights for strength training and exercise ... Atlantic Spine Center . , “Body position is everything,” Dr. Chang says. “Improper ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... Population Health and Clinical Integration company, announced today that its iClinic V12.2 solution ... (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize team-based ...
Breaking Medicine News(10 mins):